📰 Jon Yu News
Jon Yu News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Jon Yu. Real-time updates on events, politics, business and more.
February 15, 2024
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of...
January 3, 2024
CAPE CANAVERAL, Fla., Jan. 03, 2024 -- Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Executive Officer of...
November 13, 2023
WOBURN, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new...
November 8, 2023
CAPE CANAVERAL, Fla., Nov. 08, 2023 -- Vaxxinity, Inc. , a U.S. company pioneering the development of a new class of medicines, today reported financial results for the third quarter ended...
August 29, 2023
CAPE CANAVERAL, Fla., Aug. 29, 2023 -- Vaxxinity, Inc. ; class=js-l-obf link link--blue
August 16, 2023
Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies WOBURN, Mass.,... -Today at 08:01 am- MarketScreener
August 16, 2023
Data published in the Journal of Pharmaceutical Sciences support further development of caffeine as a viscosity reducing agent for subcutaneous formulations of monoclonal antibodies
August 10, 2023
Phase 2a data published in The Lancet’s eBioMedicinesupports further development of UB-311
August 9, 2023
CAPE CANAVERAL, Fla., Aug. 09, 2023 -- Vaxxinity, Inc. ; class=js-l-obf link link--blue
August 8, 2023
WOBURN, Mass., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. ( Nasdaq: CMRA ), a life sciences company developing a new generation of biologic medicines to improve